Bauer, Martin

[["dc.bibliographiccitation.firstpage","436"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Central European Journal of Medicine"],["dc.bibliographiccitation.lastpage","442"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Heetfeld, Maximilian"],["dc.contributor.author","Crozier, Thomas A."],["dc.contributor.author","Schafdecker, Hans G."],["dc.contributor.author","Poeschl, Rupert"],["dc.contributor.author","Wiese, Christoph Hermann"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, Jose Maria"],["dc.date.accessioned","2018-11-07T09:22:14Z"],["dc.date.available","2018-11-07T09:22:14Z"],["dc.date.issued","2013"],["dc.description.abstract","Outpatient surgery is increasingly being performed on patients with pre-existing cardiovascular and pulmonary disorders. These are relevant for anesthesia because of the inherent risk of hemodynamic instability. This study compared the hemodynamic course in ASA III patients undergoing knee arthroscopy with either peripheral block of the femoral and sciatic nerves or general anesthesia. We searched our patient database for ASA III patients who had undergone knee arthroscopy between 2005 and 2010. This is routinely performed in either regional or general anesthesia, and the patients were stratified according to the anesthetic. Hemodynamic parameters, process times, complications and postoperative pain documented in the charts were evaluated and compared. 130 ASA III outpatients underwent knee arthroscopy during the observation period. Regional anesthesia alone (n=65) was sufficient in 96%. Heart rate was more stable and blood pressure decreased less under regional than under general anesthesia (systolic pressure - 11 +/- 8% versus - 28 +/- 9%; p < 0.001). Patients with general anesthesia (n=65) required more circulatory support. Establishing the nerve block takes longer than inducing general anesthesia, but this was performed ahead of time and thus had no effect on work flow. The groups did not differ with regard to complication rates, and intensity of postoperative pain or satisfaction with the anesthetic. No patient showed evidence of nerve damage or neurological deficits. Peripheral nerve block provides a more stable hemodynamic course than general anesthesia in ASA III patients undergoing knee arthroscopy. (C) Versita Sp. z o.o."],["dc.identifier.doi","10.2478/s11536-012-0143-4"],["dc.identifier.isi","000320283200013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29292"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Versita"],["dc.relation.issn","1644-3640"],["dc.relation.issn","1895-1058"],["dc.title","Peripheral nerve blocks give greater hemodynamic stability than general anesthesia for ASA III patients undergoing outpatient knee arthroscopy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","233"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","The International Journal of Artificial Organs"],["dc.bibliographiccitation.lastpage","239"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Hinz, Jose"],["dc.contributor.author","Molder, Jan Martin"],["dc.contributor.author","Hanekop, Gerd-Gunnar"],["dc.contributor.author","Weyland, Andreas"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Kazmaier, Stephan"],["dc.date.accessioned","2018-11-07T09:26:14Z"],["dc.date.available","2018-11-07T09:26:14Z"],["dc.date.issued","2013"],["dc.description.abstract","Purpose: The goal of this investigation was to examine the influence of two oxygenators with different membranes, made of either polypropylene (PPL) or polymethylpentane (PMP), on the plasma concentration of sevoflurane during cardiopulmonary bypass. Methods: The concentrations of sevoflurane during cardiopulmonary bypass were examined in patient plasma, endotracheal tubes, cardiotomy reservoirs and the outlets of the heart-lung oxygenators in twenty patients who underwent elective heart surgery. Results: The sevoflurane losses are smaller in cardiopulmonary bypass when using a polymethylpentane versus a polypropylene oxygenator. Ten minutes after beginning cardiopulmonary bypass, the sevoflurane plasma concentration in the PPL oxygenator group compared to the PMP oxygenator group fell significantly (PPL 0.48-1.79 (0.93) vs. PMP 0.80-2.15 (1.56) mu L x 100 mL(-1), p = 0.02). This difference persisted until ten minutes after the termination of cardiopulmonary bypass. Conclusion: The results of this study show that using a polymethylpentane membrane oxygenator rather than a polypropylene oxygenator significantly reduces the losses of sevoflurane, resulting in higher plasma concentrations and greater depth of anesthesia."],["dc.identifier.doi","10.5301/ijao.5000208"],["dc.identifier.isi","000320894500001"],["dc.identifier.pmid","23504814"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30252"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wichtig Editore"],["dc.relation.issn","0391-3988"],["dc.title","Reduced sevoflurane loss during cardiopulmonary bypass when using a polymethylpentane versus a polypropylene oxygenator"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","969"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Artificial Organs"],["dc.bibliographiccitation.lastpage","979"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Heidrich, Florian"],["dc.contributor.author","Sossalla, Samuel T."],["dc.contributor.author","Schotola, Hanna"],["dc.contributor.author","Vorkamp, Tobias"],["dc.contributor.author","Ortmann, Philipp"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Coskun, Kasim Oguz"],["dc.contributor.author","Rajab, Taufiek K."],["dc.contributor.author","Friedrich, Martin"],["dc.contributor.author","Sohns, Christian"],["dc.contributor.author","Hinz, Jose"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Schmitto, Jan Dieter"],["dc.date.accessioned","2018-11-07T08:37:19Z"],["dc.date.available","2018-11-07T08:37:19Z"],["dc.date.issued","2010"],["dc.description.abstract","We established a stable and reproducible animal model of chronic heart failure (CHF) in sheep to investigate biomolecular changes. Therefore, two biomarkers, adenosine monophosphate-activated protein kinase (AMPK) and vascular endothelial growth factor-A (VEGF-A) were examined to reveal their role during chronic ischemic conditions of the heart. AMPK was studied because it plays an important role in cellular energy homeostasis and its upregulation is associated with myocardial ischemia, whereas VEGF-A was studied because it acts as an important signaling protein for neoangiogenesis. We examined 15 juvenile sheep (mean weight, 78 +/- 4 kg; control, n = 3; ShamOP, n = 2; coronary microembolization [CME], n = 10). CHF was induced under fluoroscopic guidance by multiple sequential microembolizations (MEs) through bolus injection of polysterol microspheres (90 mu m, n = 25.000) into the left main coronary artery. CME was repeated up to three times at 2- to 3-week intervals until animals started to develop stable signs of CHF. All animals were followed for 3 months. Phosphorylation of AMPK, marking the activated protein form, was detected by Western blotting. VEGF-A and vascular endothelial growth factor-receptor 2 (VEGF-R2) mRNA were detected by real-time polymerase chain reaction. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used as a reference housekeeping gene. All 10 CHF animals developed clinical signs of CHF as indicated by a significant decrease of cardiac output, decreased ejection fraction, as well as occurrence of tachycardia and tachypnoea. Western blots showed significant phosphorylation of AMPK in CME animals compared to the control group (phospho-adenosine monophosphate-activated protein kinase a) (GAPDH control: 0.0, CME left ventricle [LV]: 0.39 +/- 0.20, CME right ventricle [RV]: 0.53 +/- 0.30; P < 0.05). VEGF-A and VEGF-R2 expression in CME animal myocardium was within the range of the control group, but this data did not reach statistical significance due to the small size of this group. While microinjection was performed into the left main coronary artery, phosphorylation of AMPK and expression of VEGF-A and VEGF-R2 were significantly higher in the RV than in the LV. Multiple sequential intracoronary MEs can effectively induce myocardial dysfunction with clinical and biomolecular signs of chronic ischemic cardiomyopathy. Quantitative analysis of biomolecular markers showed a significantly higher phosphorylation of AMPK in CHF animals compared with control myocardium."],["dc.identifier.doi","10.1111/j.1525-1594.2010.01121.x"],["dc.identifier.isi","000284588300018"],["dc.identifier.pmid","21092039"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18501"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","6th International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion"],["dc.relation.eventlocation","Boston, MA"],["dc.relation.issn","1525-1594"],["dc.relation.issn","0160-564X"],["dc.title","The Role of Phospho-Adenosine Monophosphate-Activated Protein Kinase and Vascular Endothelial Growth Factor in a Model of Chronic Heart Failure"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","198"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Journal of Cardio-Thoracic Surgery"],["dc.bibliographiccitation.lastpage","205"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Schotola, Hanna"],["dc.contributor.author","Bräuer, Anselm"],["dc.contributor.author","Meyer, Katharina A. E."],["dc.contributor.author","Hinz, José"],["dc.contributor.author","Schöndube, Friedrich Albert"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Mohite, Prashant Nanasaheb"],["dc.contributor.author","Danner, Bernd Christoph"],["dc.contributor.author","Sossalla, Samuel Tobias"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.date.accessioned","2018-11-07T09:36:49Z"],["dc.date.available","2018-11-07T09:36:49Z"],["dc.date.issued","2014"],["dc.description.abstract","Ticagrelor (BriliqueA (R)) is a novel reversible platelet inhibitor at P2Y12 receptor used in patients with acute coronary syndrome and patients undergoing percutaneous coronary interventions. Unlike clopidogrel (PlavixA (R)), ticagrelor has a quicker offset of action, and therefore, it seems that platelet function recovers faster on discontinuation of therapy. These drugs sometimes cannot be stopped before coronary artery bypass grafting due to the risk of stent thrombosis or in case of emergency operations. Therefore, we investigated whether the continued preoperative use of ticagrelor influences the perioperative course of cardiac surgical patients. The perioperative course and clinical outcomes of patients preoperatively receiving ticagrelor + acetylsalicylic acid (ASA) (n = 32) or clopidogrel + ASA (n = 49) until cardiac surgery, performed at University of Goettingen between January 2012 and December 2012, were studied. The study was designed as a retrospective observational study. The observation period started with the surgery and ended after 3 days. P < 0.05 was considered statistically significant. Preoperative data and intraoperative characteristics were almost similar among the groups. In the first 24 h, the median blood loss was 850 [780-1600] ml in the ticagrelor group and 680 [400-860] ml in the clopidogrel group (P = 0.0006). Furthermore, the median red blood cell transfusion (P = 0.0031), the median pooled platelet transfusion (P = 0.0012), the median prothrombin complex concentrate use (P = 0.0114) and the median fibrinogen use (P = 0.0118) were significantly higher in the ticagrelor group compared with the clopidogrel group. However, there was no statistical significance between the two groups regarding intensive care unit and hospital stay, mechanical ventilation time, incidence of acute kidney injury and mortality. Hence, a tendency towards more rethoracotomies due to bleeding in the ticagrelor group was observed (P = 0.0632). In cardiac surgical patients who are treated with ticagrelor + ASA until surgery, ticagrelor therapy is associated with a significantly higher blood loss, a significantly higher use of blood products and coagulation factors and higher incidence of rethoracotomies for bleeding compared with patients treated with clopidogrel + ASA."],["dc.identifier.doi","10.1093/ejcts/ezt571"],["dc.identifier.isi","000344968300011"],["dc.identifier.pmid","24420365"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32700"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1873-734X"],["dc.relation.issn","1010-7940"],["dc.title","Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]